Pregnancy and the Patient with Inflammatory Bowel Disease: Fertility, Treatment, Delivery, and Complications

Gastroenterology Clinics of North America

Volumn 45, Issue 2, 2016, Pages 285-301

  McConnell, Ryan A ^a   Mahadevan, Uma ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast feeding; Crohn disease; Drug related side effects and adverse reactions; Fertility; Inflammatory bowel disease; Obstetric delivery; Pregnancy; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AMOXICILLIN PLUS CLAVULANIC ACID; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; GOLIMUMAB; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; NATALIZUMAB; OLSALAZINE; PREDNISONE; SALAZOSULFAPYRIDINE; TIOGUANINE; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; VEDOLIZUMAB; AMINOSALICYLIC ACID DERIVATIVE; ANTIINFECTIVE AGENT; BIOLOGICAL PRODUCT; GASTROINTESTINAL AGENT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; BREAST FEEDING; COLITIS; CROHN DISEASE; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG MEGADOSE; DRUG SAFETY; FEMALE FERTILITY; FEMALE INFERTILITY; GASTROINTESTINAL SURGERY; HUMAN; INFECTION; INFLAMMATORY BOWEL DISEASE; MALE FERTILITY; MALE INFERTILITY; NONHUMAN; OBSTETRIC DELIVERY; OLIGOSPERMIA; PELVIS SURGERY; PLACENTAL TRANSFER; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; REVIEW; RISK FACTOR; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW (TOPIC); ULCERATIVE COLITIS; FEMALE; INFERTILITY, FEMALE; INFERTILITY, MALE; INFLAMMATORY BOWEL DISEASES; MALE; PREGNANCY COMPLICATIONS; PREGNANCY RATE; PROCEDURES;

ADALIMUMAB; AMINOSALICYLIC ACIDS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; BREAST FEEDING; BUDESONIDE; CERTOLIZUMAB PEGOL; DELIVERY, OBSTETRIC; FEMALE; GASTROINTESTINAL AGENTS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFERTILITY, FEMALE; INFERTILITY, MALE; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; MALE; NATALIZUMAB; PREDNISONE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY RATE;

EID: 84977178278     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2016.02.006     Document Type: Review

References (95)

1. Kappelman M.D., Rifas-Shiman S.L., Kleinman K., et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007, 5:1424-1429.
2. Marri S.R., Ahn C., Buchman A.L. Voluntary childlessness is increased in women with inflammatory bowel disease. Inflamm Bowel Dis 2007, 13:591-599.
3. Tavernier N., Fumery M., Peyrin-Biroulet L., et al. Systematic review: fertility in non-surgically treated inflammatory bowel disease. Aliment Pharmacol Ther 2013, 38:847-853.
4. Selinger C.P., Eaden J., Selby W., et al. Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. J Crohns Colitis 2013, 7:e206-e213.
5. Mountifield R., Bampton P., Prosser R., et al. Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions. Inflamm Bowel Dis 2009, 15:720-725.
6. Ording Olsen K., Juul S., Berndtsson I., et al. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology 2002, 122:15-19.
7. Nielsen O.H., Andreasson B., Bondesen S., et al. Pregnancy in ulcerative colitis. Scand J Gastroenterol 1983, 18:735-742.
8. Ban L., Tata L.J., Humes D.J., et al. Decreased fertility rates in 9639 women diagnosed with inflammatory bowel disease: a United Kingdom population-based cohort study. Aliment Pharmacol Ther 2015, 42:855-866.
9. Timmer A., Bauer A., Dignass A., et al. Sexual function in persons with inflammatory bowel disease: a survey with matched controls. Clin Gastroenterol Hepatol 2007, 5:87-94.
10. Senates E., Colak Y., Erdem E.D., et al. Serum anti-Mullerian hormone levels are lower in reproductive-age women with Crohn's disease compared to healthy control women. J Crohns Colitis 2013, 7:e29-e34.
11. Waljee A., Waljee J., Morris A.M., et al. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut 2006, 55:1575-1580.
12. Beyer-Berjot L., Maggiori L., Birnbaum D., et al. A total laparoscopic approach reduces the infertility rate after ileal pouch-anal anastomosis: a 2-center study. Ann Surg 2013, 258:275-282.
13. Mortier P.E., Gambiez L., Karoui M., et al. Colectomy with ileorectal anastomosis preserves female fertility in ulcerative colitis. Gastroenterol Clin Biol 2006, 30:594-597.
14. Pabby V., Oza S.S., Dodge L.E., et al. In vitro fertilization is successful in women with ulcerative colitis and ileal pouch anal anastomosis. Am J Gastroenterol 2015, 110:792-797.
15. Paffoni A., Ferrari S., Vigano P., et al. Vitamin D deficiency and infertility: insights from in vitro fertilization cycles. J Clin Endocrinol Metab 2014, 99:E2372-E2376.
16. Choi J.M., Lebwohl B., Wang J., et al. Increased prevalence of celiac disease in patients with unexplained infertility in the United States. J Reprod Med 2011, 56:199-203.
17. El-Tawil A.M. Zinc deficiency in men with Crohn's disease may contribute to poor sperm function and male infertility. Andrologia 2003, 35:337-341.
18. Toovey S., Hudson E., Hendry W.F., et al. Sulphasalazine and male infertility: reversibility and possible mechanism. Gut 1981, 22:445-451.
19. French A.E., Koren G. Effect of methotrexate on male fertility. Can Fam Physician 2003, 49:577-578.
20. Suominen J.S., Wang Y., Kaipia A., et al. Tumor necrosis factor-alpha (TNF-alpha) promotes cell survival during spermatogenesis, and this effect can be blocked by infliximab, a TNF-alpha antagonist. Eur J Endocrinol 2004, 151:629-640.
21. Mahadevan U., Terdiman J.P., Aron J., et al. Infliximab and semen quality in men with inflammatory bowel disease. Inflamm Bowel Dis 2005, 11:395-399.
22. O'Toole A., Nwanne O., Tomlinson T. Inflammatory bowel disease increases risk of adverse pregnancy outcomes: a meta-analysis. Dig Dis Sci 2015, 60:2750-2761.
23. Stephansson O., Larsson H., Pedersen L., et al. Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden. Inflamm Bowel Dis 2011, 17:795-801.
24. Ban L., Tata L.J., Fiaschi L., et al. Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications. Gastroenterology 2014, 146:76-84.
25. Mahadevan U., Sandborn W.J., Li D.K., et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 2007, 133:1106-1112.
26. Boyd H.A., Basit S., Harpsoe M.C., et al. Inflammatory bowel disease and risk of adverse pregnancy outcomes. PLoS One 2015, 10:e0129567.
27. Broms G., Granath F., Linder M., et al. Complications from inflammatory bowel disease during pregnancy and delivery. Clin Gastroenterol Hepatol 2012, 10:1246-1252.
28. Oron G., Yogev Y., Shcolnick S., et al. Inflammatory bowel disease: risk factors for adverse pregnancy outcome and the impact of maternal weight gain. J Matern Fetal Neonatal Med 2012, 25:2256-2260.
29. Bengtson M., Martin C.F., Aamodt G., et al. Insufficient weight gain during pregnancy in maternal IBD predicts adverse pregnancy outcomes: results from the PIANO and Norwegian registry. Gastroenterology 2015, 148:S-238. [abstract].
30. Nielsen O.H., Andreasson B., Bondesen S., et al. Pregnancy in Crohn's disease. Scand J Gastroenterol 1984, 19:724-732.
31. Norgard B., Fonager K., Sorensen H.T., et al. Birth outcomes of women with ulcerative colitis: a nationwide Danish cohort study. Am J Gastroenterol 2000, 95:3165-3170.
32. Norgard B., Hundborg H.H., Jacobsen B.A., et al. Disease activity in pregnant women with Crohn's disease and birth outcomes: a regional Danish cohort study. Am J Gastroenterol 2007, 102:1947-1954.
33. Reddy D., Murphy S.J., Kane S.V., et al. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol 2008, 103:1203-1209.
34. Broms G., Granath F., Linder M., et al. Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure. Inflamm Bowel Dis 2014, 20:1091-1098.
35. Bush M.C., Patel S., Lapinski R.H., et al. Perinatal outcomes in inflammatory bowel disease. J Matern Fetal Neonatal Med 2004, 15:237-241.
36. Bortoli A., Pedersen N., Duricova D., et al. Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. Aliment Pharmacol Ther 2011, 34:724-734.
37. Pedersen N., Bortoli A., Duricova D., et al. The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. Aliment Pharmacol Ther 2013, 38:501-512.
38. Mahadevan U., Martin C.F., Sandler R.S., et al. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology 2012, 142:S-149. [abstract].
39. Nasef N.A., Ferguson L.R. Inflammatory bowel disease and pregnancy: overlapping pathways. Transl Res 2012, 160:65-83.
40. Abhyankar A., Ham M., Moss A.C. Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013, 38:460-466.
41. Julsgaard M., Norgaard M., Hvas C.L., et al. Self-reported adherence to medical treatment, breastfeeding behaviour, and disease activity during the postpartum period in women with Crohn's disease. Scand J Gastroenterol 2014, 49:958-966.
42. Ujihara M., Ando T., Ishiguro K., et al. Importance of appropriate pharmaceutical management in pregnant women with ulcerative colitis. BMC Res Notes 2013, 6:210.
43. Nguyen G.C., Boudreau H., Harris M.L., et al. Outcomes of obstetric hospitalizations among women with inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol 2009, 7:329-334.
44. Mahadevan U., Martin C.F., Dubinsky M., et al. Exposure to anti-TNFα therapy in the third trimester of pregnancy is not associated with increased adverse outcomes: results from the PIANO registry. Gastroenterology 2014, 146:S-170. [abstract].
45. Ananthakrishnan A.N., Cheng A., Cagan A., et al. Mode of childbirth and long-term outcomes in women with inflammatory bowel diseases. Dig Dis Sci 2015, 60:471-477.
46. Cheng A.G., Oxford E.C., Sauk J., et al. Impact of mode of delivery on outcomes in patients with perianal Crohn's disease. Inflamm Bowel Dis 2014, 20:1391-1398.
47. Cornish J.A., Tan E., Teare J., et al. The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. Dis Colon Rectum 2007, 50:1128-1138.
48. Bruce A., Black M., Bhattacharya S. Mode of delivery and risk of inflammatory bowel disease in the offspring: systematic review and meta-analysis of observational studies. Inflamm Bowel Dis 2014, 20:1217-1226.
49. Yang H., McElree C., Roth M.P., et al. Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut 1993, 34:517-524.
50. Bennett R.A., Rubin P.H., Present D.H. Frequency of inflammatory bowel disease in offspring of couples both presenting with inflammatory bowel disease. Gastroenterology 1991, 100:1638-1643.
51. Mountifield R., Andrews J.M., Bampton P. It IS worth the effort: patient knowledge of reproductive aspects of inflammatory bowel disease improves dramatically after a single group education session. J Crohns Colitis 2014, 8:796-801.
52. Food and Drug Administration. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling [Federal Register Web site]. 2014. Available at: . Accessed October 24, 2015. http://federalregister.gov/a/2014-28241.
53. Norgard B., Fonager K., Pedersen L., et al. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut 2003, 52:243-247.
54. Gallinger Z.R., Nguyen G.C. Presence of phthalates in gastrointestinal medications: is there a hidden danger?. World J Gastroenterol 2013, 19:7042-7047.
55. Nelis G.F. Diarrhoea due to 5-aminosalicylic acid in breast milk. Lancet 1989, 1:383.
56. Martinez Lopez J.A., Loza E., Carmona L. Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). Clin Exp Rheumatol 2009, 27:678-684.
57. Johns D.G., Rutherford L.D., Leighton P.C., et al. Secretion of methotrexate into human milk. Am J Obstet Gynecol 1972, 112:978-980.
58. Polifka J.E., Friedman J.M. Teratogen update: azathioprine and 6-mercaptopurine. Teratology 2002, 65:240-261.
59. Jharap B., de Boer N.K., Stokkers P., et al. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut 2014, 63:451-457.
60. Coelho J., Beaugerie L., Colombel J.F., et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 2011, 60:198-203.
61. Casanova M.J., Chaparro M., Domenech E., et al. Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol 2013, 108:433-440.
62. Akbari M., Shah S., Velayos F.S., et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis 2013, 19:15-22.
63. Hutson J.R., Matlow J.N., Moretti M.E., et al. The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy. J Obstet Gynaecol 2013, 33:1-8.
64. Mahadevan U., Martin C.F., Chambers C., et al. Achievement of developmental milestones among offspring of women with inflammatory bowel disease: the PIANO registry. Gastroenterology 2014, 146:S-1. [abstract].
65. Christensen L.A., Dahlerup J.F., Nielsen M.J., et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther 2008, 28:1209-1213.
66. McConnell R.A., Mahadevan U. Use of immunomodulators and biologics before, during, and after pregnancy. Inflamm Bowel Dis 2016, 22(1):213-223.
67. Lichtenstein G.R., Feagan B.G., Cohen R.D., et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012, 107:1409-1422.
68. Jurgens M., Brand S., Filik L., et al. Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature. Inflamm Bowel Dis 2010, 16:1634-1636.
69. Mahadevan U., Vermeire S., Wolf D.C., et al. Pregnancy outcomes after exposure to certolizumab pegol: updated results from safety surveillance. Gastroenterology 2015, 148:S-858-S-859. [abstract].
70. Nielsen O.H., Loftus E.V., Jess T. Safety of TNF-alpha inhibitors during IBD pregnancy: a systematic review. BMC Med 2013, 11:174.
71. Narula N., Al-Dabbagh R., Dhillon A., et al. Anti-TNFalpha therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2014, 20:1862-1869.
72. Matro R., Martin C.F., Wolf D.C., et al. Detection of biologic agents in breast milk and implication for infection, growth and development in infants born to women with inflammatory bowel disease: results from the PIANO registry. Gastroenterology 2015, 148:S-141. [abstract].
73. Mahadevan U., Wolf D.C., Dubinsky M., et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013, 11:286-292.
74. Kane S.V., Acquah L.A. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol 2009, 104:228-233.
75. Julsgaard M., Christensen L.A., Gibson P.R., et al. Adalimumab and infliximab levels in neonates (ERA Study). Gastroenterology 2015, 148:S-108. [abstract].
76. Arsenescu R., Arsenescu V., de Villiers W.J. TNF-alpha and the development of the neonatal immune system: implications for inhibitor use in pregnancy. Am J Gastroenterol 2011, 106:559-562.
77. Bortlik M., Duricova D., Machkova N., et al. Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children. Inflamm Bowel Dis 2014, 20:495-501.
78. Mahadevan U., Cucchiara S., Hyams J.S., et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol 2011, 106:214-223. [quiz: 224].
79. Zelinkova Z., van der Ent C., Bruin K.F., et al. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol 2013, 11:318-321.
80. Ebrahimi N., Herbstritt S., Gold R., et al. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler 2015, 21:198-205.
81. Dubinsky M., Mahadevan U., Vermeire S., et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. J Crohns Colitis 2015, 9:S361-S362. [abstract].
82. Schaufelberg B.W., Horn E., Cather J.C., et al. Pregnancy outcomes in women exposed to ustekinumab in the psoriasis clinical development program. J Am Acad Dermatol 2014, 70:AB178. [abstract].
83. Marren A., Chen Y., Frazier D., et al. Pregnancy outcomes in the tofacitinib RA safety database through April 2014. Ann Rheum Dis 2015, 74:256-257. [abstract].
84. Park-Wyllie L., Mazzotta P., Pastuszak A., et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000, 62:385-392.
85. Hviid A., Molgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ 2011, 183:796-804.
86. Lin K., Martin C.F., Dassopoulos T., et al. Pregnancy outcomes amongst mothers with inflammatory bowel disease exposed to systemic corticosteroids: results of the PIANO registry. Gastroenterology 2014, 146:S-1. [abstract].
87. Truta B. Potential risks of immunosuppressant drugs to the pregnant patient 2015, [abstract], American College of Gastroenterology, Honolulu (HI).
88. Greenberger P.A., Odeh Y.K., Frederiksen M.C., et al. Pharmacokinetics of prednisolone transfer to breast milk. Clin Pharmacol Ther 1993, 53:324-328.
89. Paziana K., Del Monaco M., Cardonick E., et al. Ciclosporin use during pregnancy. Drug Saf 2013, 36:279-294.
90. Bar-Oz B., Moretti M.E., Boskovic R., et al. The safety of quinolones-a meta-analysis of pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol 2009, 143:75-78.
91. Czeizel A.E., Rockenbauer M. A population based case-control teratologic study of oral metronidazole treatment during pregnancy. Br J Obstet Gynaecol 1998, 105:322-327.
92. Czeizel A.E., Rockenbauer M., Sorensen H.T., et al. Augmentin treatment during pregnancy and the prevalence of congenital abnormalities: a population-based case-control teratologic study. Eur J Obstet Gynecol Reprod Biol 2001, 97:188-192.
93. ACOG Committee on Obstetric Practice ACOG committee opinion No. 474: nonobstetric surgery during pregnancy. Obstet Gynecol 2011, 117:420-421.
94. Dozois E.J., Wolff B.G., Tremaine W.J., et al. Maternal and fetal outcome after colectomy for fulminant ulcerative colitis during pregnancy: case series and literature review. Dis Colon Rectum 2006, 49:64-73.
95. Barclay A.R., Russell R.K., Wilson M.L., et al. Systematic review: the role of breastfeeding in the development of pediatric inflammatory bowel disease. J Pediatr 2009, 155:421-426.